Please use this identifier to cite or link to this item: https://doi.org/10.1186/1476-4598-11-14
DC FieldValue
dc.titleKlotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma
dc.contributor.authorPoh, W.
dc.contributor.authorWong, W.
dc.contributor.authorOng, H.
dc.contributor.authorAung, M.O.
dc.contributor.authorLim, S.G.
dc.contributor.authorChua, B.T.
dc.contributor.authorHo, H.K.
dc.date.accessioned2014-10-29T01:55:02Z
dc.date.available2014-10-29T01:55:02Z
dc.date.issued2012-03-23
dc.identifier.citationPoh, W., Wong, W., Ong, H., Aung, M.O., Lim, S.G., Chua, B.T., Ho, H.K. (2012-03-23). Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma. Molecular Cancer 11 : -. ScholarBank@NUS Repository. https://doi.org/10.1186/1476-4598-11-14
dc.identifier.issn14764598
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/106103
dc.description.abstractBackground: We had previously demonstrated overexpression of fibroblast growth factor receptor-4 (FGFR4) in hepatocellular carcinoma (HCC). However, additional molecular mechanisms resulting in amplified FGFR4 signaling in HCC remain under-studied. Here, we studied the mechanistic role of its co-receptor klotho-beta (KLB) in driving elevated FGFR4 activity in HCC progression.Results: Quantitative real-time PCR analysis identified frequent elevation of KLB gene expression in HCC tumors relative to matched non-tumor tissue, with a more than two-fold increase correlating with development of multiple tumors in patients. KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4 downstream signaling. While transient repression of KLB-FGFR4 signaling decreased protein expression of alpha-fetoprotein (AFP), a HCC diagnostic marker, prolonged inhibition enriched for resistant HCC cells exhibiting increased liver stemness.Conclusions: Elevated KLB expression in HCC tissues provides further credence to the oncogenic role of increased FGFR4 signaling in HCC progression and represents a novel biomarker to identify additional patients amenable to anti-FGFR4 therapy. The restricted tissue expression profile of KLB, together with the anti-proliferative effect observed with KLB-silencing, also qualifies it as a specific and potent therapeutic target for HCC patients. The enrichment of a liver stem cell-like population in response to extended KLB-FGFR4 repression necessitates further investigation to target the development of drug resistance. © 2012 Poh et al; licensee BioMed Central Ltd.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1186/1476-4598-11-14
dc.sourceScopus
dc.subjectFGFR4
dc.subjectHepatocellular carcinoma
dc.subjectKLB
dc.subjectLiver stemness
dc.typeArticle
dc.contributor.departmentPHARMACY
dc.description.doi10.1186/1476-4598-11-14
dc.description.sourcetitleMolecular Cancer
dc.description.volume11
dc.description.page-
dc.description.codenMCOAC
dc.identifier.isiut000304542700001
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
2012-klotho_beta_overexpression_novel_target-published.pdf1.03 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

36
checked on Nov 24, 2020

WEB OF SCIENCETM
Citations

38
checked on Nov 24, 2020

Page view(s)

174
checked on Nov 29, 2020

Download(s)

5
checked on Nov 29, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.